3SOF

After many years of failure,HIV is finally poised to generate alot of revenue and may become recognized away from the penny stocks...

I am now HIV positive with a market order for the open...

I bought HIV yesterday @ $0.34. A little higher up the scan list was HYRF. Ug, I'm kicking myself . LOL PerfectSage 

Duh,I sold HYRF to buy HIV at $.29!!! Oh well,Hopefully,we will look like geniuses next week....

stout: It'll take 3-4 weeks before we look like genius's. I just want to see an up week this week. Even if it's just a cent or two.

The HIV weekly chart has all kinds of bullish pluses. The key point is, it's at the upper weekly bollinger band on heavy volume last week.


Wow, This was once a $200 dollar stock in the 2nd half of the nineties. Last time was March 2000.

Some heavy weight due diligence reports on yahoo stock message board in the last two  hours...HIV has powerful backing...

Active in the pre-market
+21.05%[email protected],000

Three months and I am still not a certified genius...Down 43% and I tenaciously hold...Before this is over,Marr may own the company...No word on China approval or factory...At worst,a good tax loss...

I might decide to get in on this tomorrow with recent news and volume jump to 10,000,000
AP
Calypte Up After China HIV Application
Thursday January 12, 10:28 am ET 
Calypte Biomedical Shares Rise After China Regulators Accept HIV Test Application for Review

LAKE OSWEGO, Ore. (AP) -- Calypte Biomedical Corp. shares jumped Thursday after the tiny medical test maker said that regulators in China have formally accepted for review a marketing application for an oral-based HIV test.

Shares of Calypte surged 7 cents, or 35 percent, to 27 cents in early morning trading on the American Stock Exchange. Shares have traded between 13 cents and 49 cents over the past 52 weeks.

The company said the Beijing Drug Administration, which accepts marketing applications on behalf of the State Food and Drug Administration of China, formally accepted an application for Calypte's Aware OMT rapid HIV test. The application will now be reviewed by state regulators.

Calypte said that China has officially announced it plans to offer voluntary HIV testing to its 1.36 billion citizens. Officials estimate China has an HIV positive population of 840,000 people, with that number expected to increase to 15 million by 2010.

Bought 10,000 shares @.26

Quote from: wrangler on January 13, 2006, 09:42:19 AM
Bought 10,000 shares @.26

Wrangler, it seems .30 is the short-term barrier.  Bumped into that in Sept as well.  Think it's ready to bust thru ?

I'm relying on Direction of MACD indicator and recent news with the increased volume. I asked eliteG for his opinoin on it. He said he would wait for consolidation and buy on the run up but I decided to go ahead and buy.
Another one that is in the same category is CEMI and it's moving up I hope I made the right choice.
Here's chart for CEMI and both might be good picks

I sold at $.24...Going down short term...Will go over $.50 when SFDA approves oral test ,9 to 90 days from now...HIV is actually controlled and manipulated by Marr Group,a large off shore"Russian"  conglomerate...

Still holding my shares. This is going to be a big player as soon as it gets China approval. Check out link.
http://www.investorshub.com/boards/board.asp?board_id=2812

There is two threads active on HIV,I'll stay with this one since I started with this one.
 
Press Release Source: Calypte Biomedical Corporation

Calypte Introduces Over-the-Counter Rapid Oral HIV Test
Thursday January 19, 8:00 am ET 
Aware(TM) OMT (Oral Fluid) HIV-1/2 Rapid Diagnostic Test Registered in the United Arab Emirates

LAKE OSWEGO, Ore., Jan. 19 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV - News) today announced the introduction of an over-the- counter (OTC) version of the Aware(TM) Oral Fluid HIV-1/2 Rapid Diagnostic Test. Calypte expects to initially launch the sale of this product in over-the-counter markets in the United Arab Emirates, where the product has been registered, and then plans to distribute it throughout the entire Middle East as additional registrations and/or approvals are obtained.
ADVERTISEMENT


The OTC Aware Oral Fluid HIV-1/2 Rapid Diagnostic Test will be distributed by Joseph and Gionis, Calypte's exclusive distributor for 22 Middle Eastern countries with a population of approximately 465 million people. According to the December 2004 UNAIDS report, there are between 230,000 and 1.5 million adults and children living with HIV within this region, of which nearly half are women.

Mr. Roger Gale, Chairman and Chief Executive Officer of Calypte stated, "We are extremely pleased to launch our newest product, an Aware Oral Fluid HIV-1/2 Rapid Diagnostic Test designed for use in an over-the-counter setting. We believe that this product will add another tool to increase detection and combat the spread of HIV virus and that the combination of an over-the-counter product with safe, oral fluid detection is well suited to reach the greatest number of individuals within the Middle Eastern countries. We look forward to a productive relationship with our newest distributor, Joseph and Gionis, as it continues to utilize its expertise in regulatory pharmaceutical and governmental affairs to facilitate the regulatory process in additional countries within its territory."

Mr. Gale, concluded, "Our launch of this over-the-counter product coincides with Arab Health, the largest Healthcare Exhibition in the Middle East, being held in Dubai, January 22-25th. We have already shipped the initial order to Joseph and Gionis in conjunction with this Exhibition and we believe we have sufficient inventory in stock to satisfy anticipated initial sales of this innovative product."

About Joseph and Gionis LLC

Joseph and Gionis is a global biotechnology consulting and distribution firm with offices in Newport Beach, California and the United Arab Emirates, specializing in new scientific developments which contribute to public health and welfare.

About Calypte Biomedical:

Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.